Evercore ISI Analyst Sees 36% Upside In Amazon – Read Why
Evercore ISI analyst Mark Mahaney raised the price target Amazon.com Inc (NASDAQ:AMZN) to $4,700 from $4,200, implying a 35.9% upside, and reiterated an Outperform.…
Why This Microsoft Analyst Expects Dividend Hike Of More Than 10%
Software giant Microsoft Corporation (NASDAQ: MSFT) customarily announces a dividend hike by the middle of September. An analyst at Morgan Stanley is expecting a 10%-plus dividend increase this time around, bringing the dividend yield to about 0.8%.
How Analysts View Palo Alto Networks Post 2021 Annual Day?
Palo Alto Networks Inc (NYSE: PANW) guided to $8 billion in FY24 revenue, implying a 23% compound annual growth rate…
Morgan Stanley Sees 12% Upside In Microsoft – Read Why
Morgan Stanley analyst Keith Weiss has raised the price target on Microsoft Corp (NASDAQ:MSFT) to $331 from $305, implying an 11.5% upside, and reiterated an…
Why This Albemarle Analyst Is Lifting Their Price Target
Albemarle Corporation (NYSE: ALB) will benefit as electric vehicle production growth accelerates, according to a RBC Capital Markets analyst.
Here’s Why Goldman Sachs Sees 44% Upside In Dell
Goldman Sachs analyst Rod Hall added Dell Technologies Inc (NYSE:DELL) to the firm’s Americas Conviction List and reiterated a Buy with a $137 price target,…
Goldman Sachs Reiterates Buy on Dell Technologies, Adds to Conviction List
Goldman Sachs analyst Rod Hall reiterates Dell Technologies (NYSE:DELL) with a Buy, adds to Conviction List.
Dave & Buster’s Stock Jumps On Q2 Earnings: 3 Analysts React To Surprisingly Strong Sales Momentum
Dave & Buster's Entertainment Inc (NYSE: PLAY) shares traded higher Friday after the company reported better-than-expected second-quarter earnings and management struck a confident tone on the earnings call.
Why Analysts See Up To 25% Upside In This Security-As-A-Service Firm?
Analysts mainly lauded Zscaler Inc's (NASDAQ: ZS) 70% year-on-year billings growth above consensus in Q4, network and raised their price targets betting on network transformation, strong security backdrop.
Why This Citius Analyst Thinks The Biopharma’s Shares Present 375% Upside Potential
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr.